{"aiVersion":"1","content":{"id":"cmsi8tfhs0004juf6k25n0j7s","slug":"when-anti-inflammatory-heart-drugs-don-t-work-what-20260807","title":"When Anti‑Inflammatory Heart Drugs Don’t Work: What the Trials Tell Us","level":"MEDIUM","publishedAt":"2026-08-07T01:05:16.523Z"},"topic":{"slug":"when-anti-inflammatory-heart-drugs-don-t-work-what-20260807","category":"health"},"article":{"paragraphs":["Inflammation has been proposed as a key driver of atherosclerosis, and some trials have supported that idea while others have not. In 2017 the CANTOS trial tested canakinumab, an antibody that blocks interleukin-1β, and it reduced rates of some major cardiovascular events in people with prior heart attacks and high hsCRP. Since then, other studies have produced mixed results. The CIRT trial tested low‑dose methotrexate and did not lower cardiovascular events, and earlier drugs such as darapladib also failed to show benefit in large trials. These outcomes suggest that targeting inflammation is complex and patient selection matters.","More recently, in July 2026 AstraZeneca and Ionis reported that eplontersen did not meet the primary endpoint in a Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy, a different heart disease caused by protein build-up. Novo Nordisk’s ziltivekimab has lowered hsCRP and other markers in earlier studies, and the large ZEUS cardiovascular outcomes trial is testing whether IL-6 inhibition reduces events. Therefore, although some anti-inflammatory therapies have lowered biomarkers, not all have clearly reduced hard heart outcomes; researchers must refine who may benefit and which pathways to target."],"wordCount":184,"readTime":2},"vocabulary":[{"word":"atherosclerosis","example":"Atherosclerosis can lead to heart attacks and strokes.","phonetic":"/ˌæðəroʊskləˈroʊsɪs/","definition":"hardening of the arteries from fatty plaque that can block blood flow"},{"word":"biomarker","example":"Doctors measure hsCRP as an inflammation biomarker.","phonetic":"/ˈbaɪoʊˌmɑːrkər/","definition":"a biological measurement that shows disease activity or response"},{"word":"interleukin-6","example":"Interleukin-6 levels often rise with inflammation.","phonetic":"/ˌɪntərˈluːkɪn sɪks/","definition":"a signaling protein that can drive inflammation in blood vessels"},{"word":"primary endpoint","example":"The study did not meet the primary endpoint.","phonetic":"/ˈpraɪməri ˈɛndˌpɔɪnt/","definition":"the main outcome a trial is designed to test"}],"quiz":[{"answer":"canakinumab","question":"What antibody blocks interleukin-1β in the CANTOS trial?"},{"answer":"The CIRT trial","question":"Which trial tested low‑dose methotrexate and did not lower cardiovascular events?"},{"answer":"ZEUS cardiovascular outcomes trial","question":"What is the name of the large outcomes trial testing IL-6 inhibition?"}],"discussion":[{"question":"Do you worry about inflammation as a long-term health risk? Why or why not?"},{"question":"Have you changed your diet or exercise because of heart health news? What did you try?"},{"question":"What would make you trust a new heart medicine more: biomarker change or fewer heart attacks?"},{"question":"Would you join a clinical trial if doctors invited you? Why or why not?"}]}